USE OF MICRO-RIBONUCLEIC ACID (MIRNA) TO DIAGNOSE TRANSPLANT REJECTION AND TOLERANCE OF IMMUNOSUPPRESSION THERAPY

摘要

The present invention relates to the discovery that the expression levels of some microRNAs (miRNAs) can use a diagnostic signature to predict transplant outcomes in a transplant recipient. Thus, in various embodiments described herein, the methods of the invention relate to methods of diagnosing a transplant subject for acute rejection such as acute cellular rejection (ACR), methods of predicting a subject's risk of having or developing ACR and methods of assessing in a subject the likelihood of a successful or failure minimization of immunosuppression therapy (IST) dosage from standard ranges.